The Gairdner Foundation is pleased to announce the 2025 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical and global health research and discoveries.

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Utility stocks are often considered a safe haven during economic troubles, and Dominion Energy (NYSE: D) stands out as a prime candidate. With a substantial customer base of 3.6 million in Virginia, ...

Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston ...

The company’s recent approval of Alyftrek for CF and the anticipated launch of Journavx for acute pain management mark important milestones in its growth strategy. Journavx, a non-opioid ...